<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19857">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702311</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00056041</org_study_id>
    <nct_id>NCT01702311</nct_id>
  </id_info>
  <brief_title>Point-of-Care Glucose Testing and Insulin Supplementation</brief_title>
  <acronym>POC</acronym>
  <official_title>Benefits of Point-of-Care Glucose Testing and Insulin Supplementation at Bedtime in Insulin Treated Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of
      diabetes and hyperglycemia in the hospital setting. POC testing aims at collecting
      information on BG levels at different time points during the day in order to assess glycemic
      control and to guide insulin adjustment/correction doses. Although POC testing provides
      insights into day-to-day excursions in BG levels, bedtime BG testing triggers the use of
      insulin supplements that may result in increased frequency of hypoglycemia and is expensive
      with an estimated annual cost in hospitals of several hundreds of millions of dollars in the
      U.S. Accordingly, this pilot study aims to assess the utility of POC and insulin
      supplementation (correction doses) at bedtime in improving glycemic control and in
      preventing hypoglycemia in non-ICU patients with type 2 diabetes mellitus (T2DM).  A total
      of 250 non-ICU medical and surgical patients treated with basal bolus regimen will undergo
      POC testing before meals and bedtime (standard of care) and half of the patients will
      receive insulin correction doses at bedtime for BG &gt; 140 mg/dL following a sliding scale
      protocol, while the other half will be followed without insulin supplementation at bedtime
      except for extreme hyperglycemia (BG &gt; 350 mg/dl). Patients will be recruited at Emory
      University Hospital and Grady Memorial Hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The value of POC testing and use of insulin supplements (correction doses) in particular at
      bedtime, has not been prospectively evaluated in insulin-treated patients with T2DM. In the
      non-ICU setting, practice guidelines for the management of hyperglycemia in patients with
      T2DM favor the use of physiologic (basal-nutritional-correction dose) insulin regimens over
      sliding scale regular insulin. POC testing is invasive and painful, and has the limitation
      of providing glycemic profile that is an incomplete picture of BG excursions and is not
      always an accurate method to monitor glucose compared to laboratory assays in addition to
      the major expense in health care delivery. The overall objective of this proposal is to
      conduct the first prospective randomized controlled trial (RCT) to determine the POC glucose
      testing and use of insulin supplementation at bedtime in improving glycemic control and in
      preventing hypoglycemia in insulin-treated non-ICU patients with T2DM. The central
      hypothesis of this proposal is that routine BG measurement and insulin supplementation at
      bedtime does not improve glycemic control or reduce frequency of hypoglycemia in insulin
      treated medicine and surgery patients with T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>mean fasting blood glucose</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome of the study is to compare differences in mean fasting BG levels between patients receiving insulin supplements at bedtime compared to those without insulin supplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean daily BG and number of BG within target</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcomes include differences between treatment groups in any of the following measures: mean daily BG and number of BG within target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemia (BG &lt; 70 mg/dl) and severe hyperglycemia (BG&gt;300 mg/dl)</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcomes include the number of hypoglycemia (BG &lt; 70 mg/dl) and severe hyperglycemia (BG&gt;300 mg/dl) among both the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily dose of insulin</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the daily dose of insulin used among both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Length of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mortality is defined as death occurring during admission or during the hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial infections (CDC)</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Nosocomial infections during hospital stay as per the CDC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pneumonia (CDC criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremia</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bacteremia with SIRS/Sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>participants will be followed for the duration of hospital stay, an expected average of 6 days</measure>
    <time_frame>daily while in hospital for up to 10 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Respiratory failure, defined as PaO2 value &lt; 60 mm Hg while breathing air or a PaCO2 &gt; 50 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure [rise &gt;50% of baseline or creatinine &gt;2.5 mg/dl]</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Acute renal failure [rise &gt;50% of baseline or creatinine &gt;2.5 mg/dl]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>qhs supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will have acqhs and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no qhs supplementation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will have ac, qhs and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin hs supplementation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hs insulin Aspart (Novolog)</intervention_name>
    <description>hs insulin aspart supplementation based on BG value in the qhs supplementation arm.</description>
    <arm_group_label>qhs supplementation</arm_group_label>
    <other_name>Aspart (Novolog)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients with a known history of T2DM for &gt; 3 months

          2. Age 18-80 years

          3. Home treatment with either diet alone, any combination of oral antidiabetic agents,
             non-insulin injectables or insulin therapy

          4. BG &gt; 140 mg and &lt; 400 mg/dL without laboratory evidence of diabetic ketoacidosis

        Exclusion Criteria:

          1. Hyperglycemia without a history of diabetes

          2. Acute critical illness admitted to the ICU or expected to require ICU admission

          3. Receiving continuous insulin infusion

          4. Clinically relevant hepatic disease

          5. Patients on corticosteroid therapy

          6. Patients with creatinine â‰¥ 3.5 mg/dl

          7. Subjects unable to sign consent

          8. Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <phone>404-778-1664</phone>
    <email>geumpie@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Smiley Dawn, MD</last_name>
    <email>dsmiley@emory.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Umpierrez, MD</last_name>
      <phone>404-778-1665</phone>
    </contact>
    <contact_backup>
      <last_name>Dawn Smiley, MD</last_name>
      <phone>404-778-1664</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Smiley</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>May 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Point of care testing</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Basal bolus insulin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin aspart</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
